Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Puma Biotechnology reports revenue growth and strategic advancements in oncology

Puma Biotechnology's Q4 2022 performance reflects revenue growth, cost reductions, and a focus on improving NERLYNX sales.
The company faces challenges in addressing financial losses, FDA trial requirements, and optimizing commercial strategies.
Opportunities in advancing clinical programs, FDA discussions, and market expansion present avenues for future growth and innovation.
Overall, Puma's strategic focus on revenue enhancement, cost control, and innovative treatments positions them for continued progress in the oncology market.

Puma Biotechnology reports solid Q1 earnings, eyes oncology expansion

Puma Biotechnology's Q1 2023 performance driven by strong NERLYNX sales and revenue growth.
Focus on in-licensing alisertib and optimizing expenses for sustained profitability.
Challenges include competition, patent issues, and trial enrollment hurdles.
Opportunities lie in expanding alisertib's indications and in-licensing assets for growth.

Puma Biotechnology reports revenue growth and advances in clinical trials

Puma Biotechnology's Q2 2023 performance showcased revenue growth driven by NERLYNX sales and promising results from alisertib trials. Despite challenges in NERLYNX prescriptions and FDA expectations, strategic initiatives aim to boost sales and advance clinical development. Opportunities in commercial strategies and clinical trials present avenues for future growth.

Puma Biotechnology reports solid Q3 earnings amidst sales challenges

Puma Biotechnology reported solid financial performance in Q3 2023 despite challenges in NERLYNX sales.
The company's focus on improving sales, pursuing clinical trials, and reducing expenses positions it for future growth.
Opportunities lie in enhancing NERLYNX sales, diversifying the product portfolio, and achieving clinical milestones.
Navigating challenges in sales and portfolio diversification while capitalizing on opportunities will be key for Puma's success.

Puma Biotechnology reports stable Q4 earnings amidst prescription challenges

Puma Biotechnology's Q4 2023 performance reflects solid revenue figures and a focus on profitability despite prescription declines.
The company's strengths lie in its innovative trials, commercial strategies, and optimistic revenue projections for the future.
Challenges include prescription decreases and inventory impacts, while opportunities exist in diversification, engagement enhancement, and market differentiation.

Puma Biotechnology reports revenue growth and strategic expansion plans

Puma Biotechnology's Q1 2024 performance reflects revenue growth and strategic initiatives to drive sales and enhance profitability.
While facing challenges in maintaining NERLYNX sales and managing expenses, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, financial stability, and market expansion, Puma is poised for continued growth and success in the biotechnology sector.
Investors should monitor Puma's progress in clinical trials, revenue diversification, and cost management for insights into its future performance.

Puma Biotechnology reports strong revenue, eyes product approvals for growth

Puma Biotechnology's Q2 2024 performance reflects solid revenue generation and strategic investment in innovation.
While facing challenges such as declining new prescriptions and a net loss, the company maintains a focus on cost management.
Opportunities lie in product approvals, revenue growth, and leveraging financial stability for future growth initiatives.
Overall, Puma's financial outlook remains positive, supported by a strong product pipeline and prudent financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO of Puma Biotechnology, will present a corporate update at the H.C. Wainwright Global Investment Conference beginning on 9/11/23.

Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

LOS ANGELES--(BUSINESS WIRE)--Puma has been notified by the FDA that its IND has been reviewed, and Puma can proceed with clinical development of alisertib monotherapy for SCLC.

Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.

Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President and CEO Maximo Nougues - CFO Jeff Ludwig - CCO Conference Call Participants Ed White - H.C. Wainwright Divya Rao - TD Cowen and Company Alex Hammond - Bank of America Operator Good afternoon.

Puma Biotechnology, Inc. (PBYI) Q2 2023 Earnings Call Transcript

Puma Biotech (PBYI) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.21 per share a year ago.

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue operating results for 2Q-2023 on Aug. 3 and follow with a conference call at 1:30 pm PT.

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

Genmab - ADR

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Genmab A/S Sponsored ADR (GMAB). But which of these two stocks is more attractive to value investors?

PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?

Ligand Pharmaceuticals

Mesoblast

Vaxcyte

Protagonist Therapeutics

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.

5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good

LOS ANGELES--(BUSINESS WIRE)--Biomarker findings from a P II study of alisertib+paclitaxel v. paclitaxel alone in met. HR+ and triple neg breast cancer were presented at ASCO 2023.

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.

Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now

Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chairman, President and CEO Maximo Nougues - Chief Financial Officer Jeff Ludwig - Chief Commercial Officer Conference Call Participants Ed White - H.C. Wainwright Divya Rao - TD Cowen Operator Good afternoon.

Puma Biotechnology, Inc. (PBYI) Q1 2023 Earnings Call Transcript

Puma Biotech (PBYI) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to loss of $0.08 per share a year ago.

Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its financial results for the first quarter of 2023 after market close, followed by a conference call, on May 4, 2023.

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Results of Puma's Phase II TBCRC041 trial of alisertib in patients with endocrine-resistant advanced breast cancer published online in JAMA Oncology.

Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

Puma Biotechnology's (PBYI) Q4 2022 loss is wider than estimates, Revenues beat the same.

Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director of IR Alan Auerbach - CEO, President and Chairman Maximo Nougues - CFO Jeff Ludwig - Chief Commercial Officer Conference Call Participants Dave Rao - Cowen and Company Sahil Kazmi - B. Riley Securities Operator Good afternoon.

Puma Biotechnology, Inc. (PBYI) Q4 2022 Earnings Call Transcript

LOS ANGELES--(BUSINESS WIRE)--On March 2, 2023, Puma Biotechnology issued its financial results for the fourth quarter and full year ended Dec. 31, 2022.

Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will attend Cowen's 43rd Annual Health Care Conference, which will be held March 6 – 8, 2023 at the Boston Marriott Copley Place in Boston. Mr. Auerbach will participate in a Breast and Lung Cancer Panel Discussion on March 7 at 10:30 a.m. ET.

Puma Biotechnology to Participate in a Panel Discussion at Cowen's 43rd Annual Health Care Conference

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 2, 2023, following the release of its fourth quarter and full year 2022 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international).

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results

LOS ANGELES--( BUSINESS WIRE )--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer were updated to include an addition involving neratinib (NERLYNX®).

Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation

LOS ANGELES--( BUSINESS WIRE )--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:00 a.m. PST/2:00 p.m. EST on January 19 at the virtual B. Riley Securities' 3rd Annual Oncology Conference. A live webcast of Mr. Auerbach's presentation will be accessible via registration on the event website at https://brileyoncology22.sequireevents.com/. A replay of the presentation will be available at the same address.

Puma Biotechnology to Present at B. Riley Securities' 3rd Annual Oncology Conference

Certara

CERT vs. PBYI: Which Stock Is the Better Value Option?

CERT vs. PBYI: Which Stock Should Value Investors Buy Now?

LOS ANGELES--( BUSINESS WIRE )--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, will refer to in meetings beginning Monday, January 9, 2023. The updated presentation includes, among other things, the Company's preliminary estimate that it sold approximately 3,323 bottles of NERLYNX® in the United States in the fourth quarter of 2022. This preliminary estimate is subject to completion of the Company's customary closing and review procedures and could change based on that process. The updated slides will be available on the Investors section of Puma's website at https://investor.pumabiotechnology.com/sec-filings/all-filings/default.aspx.

Puma Biotechnology Releases Updated Corporate Presentation

The company's CEO bought $2.5 million worth of company stock.

News for Puma Biotechnology Stock (PBYI)